Jennifer L Clarke

List of Publications by Year
in descending order

74 papers	3,707 citations	236925 25 h-index	138484 58 g-index
75 all docs	75 docs citations	75 times ranked	5844 citing authors

#	Article	IF	Citations
1	Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival. Journal of the National Cancer Institute, 2022, 114, 446-457.	6.3	11
2	EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathologica, 2022, 143, 109-113.	7.7	11
3	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. Journal of Clinical Investigation, 2022, 132, .	8.2	32
4	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro-Oncology, 2022, 24, 1471-1481.	1.2	14
5	Prospective genomically guided identification of â€œearly/evolvingâ€•and â€œundersampledâ€•IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	1.2	10
6	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 2567-2578.	7.0	20
7	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. Neurosurgery, 2022, 90, 124-130.	1.1	17
8	Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.7	22
9	Pre-surgery immune profiles of adult glioma patients. Journal of Neuro-Oncology, 2022, 159, 103-115.	2.9	7
10	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2021, 27, 1048-1057.	7.0	129
11	Current Advances in Immunotherapy for Glioblastoma. Current Oncology Reports, 2021, 23, 21.	4.0	26
12	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro-Oncology, 2021, 23, 1872-1884.	1.2	48
13	A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. Journal of Neuro-Oncology, 2021, 153, 447-454.	2.9	6
14	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research, 2021, 27, 4491-4499.	7.0	112
15	Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to â€˜Polymorphous low-grade neuroepithelial tumor of the youngâ€™. Acta Neuropathologica, 2021, 142, 595-599.	7.7	16
16	A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma. Journal of Neurosurgery: Spine, 2021, 35, 834-843.	1.7	13
17	Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. Neuro-Oncology, 2021, 23, 1974-1976.	1.2	12
18	Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. Journal of Neuro-Oncology, 2020, 146, 71-78.	2.9	5

#	Article	IF	Citations
19	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathologica Communications, 2020, 8, 151.	5.2	35
20	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neuro-Oncology Advances, 2020, 2, vdaa142.	0.7	35
21	MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-Oncology, 2020, 22, 1580-1590.	1.2	55
22	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. Journal of Neuro-Oncology, 2020, 148, 131-139.	2.9	15
23	Characterization of serial hyperpolarized 13C metabolic imaging in patients with glioma. NeuroImage: Clinical, 2020, 27, 102323.	2.7	42
24	Association of Maximal Extent of Resection of Contrast-Enhanced and Nonâ€“Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2020, 6, 495.	7.1	325
25	A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors. Neuro-Oncology Practice, 2020, 7, 376-383.	1.6	6
26	PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS. Neuro-Oncology, 2020, 22, ii166-ii166.	1.2	2
27	BIOM-13. DNA METHYLATION MARKS GLUCOCORTICOID PATHWAY RESPONSE IN DEXAMETHASONE-TREATED BRAIN TUMOR PATIENTS. Neuro-Oncology, 2020, 22, ii4-ii4.	1.2	0
28	EPID-08. PRE-SURGERY IMMUNE PROFILES OF ADULT GLIOMA PATIENTS. Neuro-Oncology, 2020, 22, ii79-ii80.	1.2	0
29	RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION. Neuro-Oncology, 2020, 22, ii194-ii194.	1.2	2
30	QOLP-12. EMBEDDING OUTPATIENT PALLIATIVE CARE INTO NEURO-ONCOLOGY CLINIC â€“ RESULTS FROM A ONE YEAR PILOT. Neuro-Oncology, 2020, 22, ii177-ii177.	1.2	1
31	SURG-15. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED DIFFUSE LOW-GRADE GLIOMA. Neuro-Oncology, 2020, 22, ii206-ii206.	1.2	0
32	EPCO-25. AN IMMUNOMETHYLOMIC PLATFORM INTEGRATING SYSTEMIC IMMUNE PROFILES AND EPIGENETIC AGE IN NEURO-ONCOLOGY. Neuro-Oncology, 2020, 22, ii74-ii74.	1.2	0
33	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii138-ii139.	1.2	0
34	PATH-22. COMPREHENSIVE ANALYSIS OF DIVERSE LOW-GRADE NEUROEPITHELIAL TUMORS WITH FGFR1 ALTERATIONS REVEALS A DISTINCT MOLECULAR SIGNATURE OF ROSETTE-FORMING GLIONEURONAL TUMOR. Neuro-Oncology, 2020, 22, ii168-ii169.	1.2	0
35	BIOM-38. PI3K/AKT/mTOR SIGNALING PATHWAY ACTIVITY IN IDH-MUTANT DIFFUSE GLIOMA. Neuro-Oncology, 2020, 22, ii9-ii10.	1.2	0
36	PATH-30. CLINICAL AND GENETIC CHARACTERISTICS OF HISTONE H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IN ADULTS. Neuro-Oncology, 2020, 22, ii170-ii171.	1.2	0

#	Article	IF	Citations
37	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii40-ii40.	1.2	0
38	NCOG-21. INTERIM RESULTS OF THREE COGNITIVE REHABILITATION STRATEGIES IN PATIENTS WITH LOWER GRADE GLIOMAS. Neuro-Oncology, 2020, 22, ii133-ii134.	1.2	2
39	SURG-18. THE IMPACT OF NEUROLOGIC IMPAIRMENTS ON THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION IN NEWLY DIAGNOSED IDH-WILD TYPE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii207-ii207.	1.2	0
40	NIMG-50. INITIAL EXPERIENCE: DETECTION OF ABERRANT HYPERPOLARIZED [1-13C]PYRUVATE METABOLISM IN PATIENTS WITH GBM PRIOR TO RESECTION. Neuro-Oncology, 2020, 22, ii159-ii159.	1.2	1
41	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathologica, 2019, 138, 877-881.	7.7	21
42	Risk factors of radiotherapyâ€induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. Journal of Magnetic Resonance Imaging, 2019, 50, 868-877.	3.4	25
43	Attitudes toward fertility and fertility preservation in women with glioma. Neuro-Oncology Practice, 2019, 6, 218-225.	1.6	5
44	Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neuro-Oncology Practice, 2019, 6, 364-374.	1.6	16
45	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 2019, 25, 477-486.	30.7	932
46	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. Neuro-Oncology, 2019, 21, vi28-vi29.	1.2	17
47	The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica, 2019, 137, 139-150.	7.7	57
48	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 632-641.	1.2	33
49	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical Cancer Research, 2018, 24, 295-305.	7.0	68
50	The genetic landscape of ganglioglioma. Acta Neuropathologica Communications, 2018, 6, 47.	5.2	130
51	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. Journal of Neuro-Oncology, 2018, 140, 477-483.	2.9	82
52	Survivorship care planning in neuro-oncology. Neuro-Oncology Practice, 2018, 5, 3-9.	1.6	10
53	Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro-Oncology, 2017, 19, 78-88.	1.2	51
54	A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemotherapy and Pharmacology, 2017, 79, 603-610.	2.3	32

#	Article	IF	Citations
55	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica, 2017, 133, 1001-1016.	7.7	245
56	Probing the phosphatidylinositol 3â€kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult lowâ€grade gliomas. Cancer, 2017, 123, 4631-4639.	4.1	43
57	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 797-804.	0.8	40
58	Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. Brain Tumor Research and Treatment, 2017, 5, 1.	1.0	67
59	Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines, 2016, 4, 24.	3.2	12
60	ACTR-32. AÂPROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS. Neuro-Oncology, 2016, 18, vi8-vi9.	1.2	0
61	Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. Journal of Neuro-Oncology, 2016, 130, 171-179.	2.9	24
62	Case-Based Review: meningioma. Neuro-Oncology Practice, 2016, 3, 120-134.	1.6	6
63	Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. Journal of Neuro-Oncology, 2016, 126, 193-200.	2.9	45
64	Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Reports in Radiology, 2015, 2015, 1-4.	0.3	16
65	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Translational Oncology, 2015, 8, 446-455.	3.7	3
66	Case-Based Review: newly diagnosed glioblastoma. Neuro-Oncology Practice, 2015, 2, 106-121.	1.6	13
67	Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro-Oncology, 2014, 16, 1255-1262.	1.2	44
68	Bevacizumab and Other Targeted Agents in the Upfront Treatment of Glioblastoma. Seminars in Radiation Oncology, 2014, 24, 273-278.	2.2	2
69	Standardization and Quality Assurance of Radiation Therapy Volumes for Adults With High-Grade Gliomas. Seminars in Radiation Oncology, 2014, 24, 259-264.	2.2	7
70	Neuroimaging. Cancer Journal (Sudbury, Mass), 2012, 18, 26-31.	2.0	24
71	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro-Oncology, 2011, 13, 1118-1124.	1.2	100
72	Recent Advances in Therapy for Glioblastoma. Archives of Neurology, 2010, 67, 279-83.	4.5	234

#	Article	IF	Citations
73	Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging. Current Neurology and Neuroscience Reports, 2009, 9, 241-246.	4.2	148
74	External Validation of the ICH Score. Neurocritical Care, 2004, 1, 53-60.	2.4	123